High-intensity exercise to improve cardiorespiratory fitness in cancer patients and survivors: A systematic review and meta-analysis

Ana Myriam Lavín-Pérez1,2,3 | Daniel Collado-Mateo2 | Xián Mayo2 | Liam Humphreys4 | Gary Liguori5 | Robert James Copeland4 | Fernando Del Villar Álvarez2 | Alfonso Jiménez2,3,4

1 Program of Epidemiology and Public Health (Interuniversity), PhD International School of the Rey Juan Carlos University, Madrid, Spain
2 Centre for Sport Studies, Rey Juan Carlos University, Madrid, Spain
3 GO fitLAB, Ingesport, Madrid, Spain
4 Advanced Wellbeing Research Centre, College of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, UK
5 University of Rhode Island, Kingston, RI, USA

Correspondence
Daniel Collado-Mateo, Centre for Sport Studies Fuenlabrada, Rey Juan Carlos University, Madrid, Spain
Email: daniel.collado@urjc.es

Funding information
The study has been funded by the Industrial Doctorate Spanish National grant program, part of the Strategic Plan on Science and Innovation Support of the Spanish Ministry of Science, Innovation and Universities. The predoctoral industry grant identification number is DIN2018-010129.

Improving cardiorespiratory fitness (CRFit) in cancer patients is crucial to increase survivorship, promote health, and improve quality of life. High-intensity training (HIT) has the potential to increase CRFit, perhaps better than other exercise modalities, but the extant evidence has yet to be fully explored. This systematic review and meta-analysis aimed to evaluate the effects of HIT on CRFit in cancer patients and survivors and to identify the optimal characteristics of the interventions (eg, cancer type, intervention timing, exercise modality, intervention's duration, and the number of minutes of high-intensity exercise in each session). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. A total of 31 articles (2515 participants) were included in the systematic review and 25 in the meta-analyses. CRFit significantly improved with HIT in comparison with a control group ($P < .00001$, SMD = 0.44 and a 95% confidence interval from 0.25 to 0.64). The results obtained in the sub-analysis were statistically significant except the comparison with the active group CRFit ($P = .13$). The results showed that higher effects could be achieved in: patients starting to exercise before treatment, interventions longer than eight weeks, programs including exclusively cardiovascular training and with a high-intensity part of session duration of at least 20 minutes.

KEYWORDS
cardiorespiratory fitness, exercise oncology, high-intensity training

1 | INTRODUCTION

Cancer remains a global public health problem despite considerable advances in prevention, treatment, and aftercare strategies. Cancer is the second leading cause of death in the United States, with ~1.7 million new cases diagnosed in 2019, more than 4800 each day.1 Cancer patients often have to pass through different treatments (surgery, chemotherapy, radiotherapy, hormone therapy, etc) which affects their health, activities of daily living,2 and cardiorespiratory fitness (CRFit). CRFit measures are clinically important due to being inversely associated with cancer-related death.3 cancer
risk and case fatality, overall morbidity, and increased health-related quality of life; up to the point of being considered an independent risk factor for cardiovascular disease. Moreover, several investigations have demonstrated a significant decrease in CRFit, measured by peak volume of oxygen consumption (VO_{2\text{peak}}), during cancer treatment, which is influenced by patients' clinical health, drug's cardiac side effects, and physical inactivity during the whole period.

Chemotherapy and drug therapies have high toxicity and can damage organs such as liver or heart. Depending on treatment course, this may leave to irreversible tissue damage. While cancer survivorship is growing, so is cardiotoxicity. Cardiotoxicity is the toxic effect of anti-cancer drugs causing “dawning of hypotension or hypertension, arrhythmias, myocardial infarction and/or thromboembolism and myocarditis”. Cardiotoxicity side effects could be manifested in a short or long term, increasing the risk of heart failure while decreasing CRFit. Thus, the benefits of exercise in survivors must also be studied to evaluate the potential effects of rehabilitation therapies on the variables that can be affected by these side effects. In this regard, physical exercise before surgery, during treatment, and as a survivor may mitigate cardiotoxicity and the impact of cancer on CRFit, quality of life, chronic fatigue, and anxiety or depression. Exercise is safe, feasible, and cost-effective; however, the optimal intensity, duration, and mode at each stage of the cancer pathway remain unclear. The consensus of exercise to cancer patients suggests; moderate-to-high intensity aerobic exercise, resistance exercise or a combination of both conduct on a frequency of 2-3 sessions per week for between 8 and 12 weeks. While most cancer-related exercise interventions have been limited to low-intensity and/or moderate-intensity exercise, evidence is emerging from randomized controlled trials (RTC) to suggest that health outcomes are as good if not better from higher intensity exercise protocols in adult cancer survivors.

High-intensity training (HIT) can induce greater improvements in CRFit than moderate continuous aerobic exercise in patients with heart failure or stroke. In cancer patients, different RTC of HIT have demonstrated improved CRFit in comparison with controls or moderate-intensity exercise. The optimal characteristics of high-intensity exercise are still unknown, and some examples of non-successful (in terms of CRFit) interventions can be read. Therefore, an in-depth evaluation of the evidence for HIT and CRFit in cancer patients is needed. Beyond CRFit, exercise produces changes in the tumor microenvironment and lactate concentration. Thus with higher intensities, these changes could be greater and affect different health outcomes. To our knowledge, two previous systematic reviews have explored the effects of high-intensity exercise on CRFit in patients with cancer. Firstly, Toohey et al conducted a systematic review without meta-analysis of nine articles showing evidence of larger CRFit improvements after high-intensity exercise and suggesting that a multi-modal (combined cardiovascular and resistance exercises) program performed three times a week increases VO_{2\text{max}} (+21.35%). Secondly, Mugele et al conducted a review and meta-analysis exploring the effects of high-intensity interval training (HIIT) on the CRFit of cancer patients and survivors, without considering resistance components and high-intensity continuous exercise. The study concluded that aerobic HIIT leads to positive outcomes compared to controls (including five studies) while the differences compared to moderate intensity are unclear (including four articles). The authors of the two reviews concluded that the optimal characteristics of a high-intensity intervention (including duration, volume, exercise type, type of cancer, and timing) were unclear and therefore required further research.

With this in mind, the present systematic review and meta-analysis aimed to evaluate the effects of any type of HIT on CRFit in cancer patients and survivors. Furthermore, we also aimed to identify the optimal characteristics of HIT interventions by analyzing effects according to; cancer type, intervention timing (pre-treatment during treatment, and post-treatment), exercise modality (with or without resistance training), the length of the intervention (number of weeks) and the duration of the high-intensity exercise in each session (number of minutes).

## METHODS

The systematic review followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. It was registered in the International prospective register of systematic reviews (PROSPERO) with the identification number CRD42020167203. A change from the registered protocol is that the results reported here are only based on CRFit. Given the large number of analyses and figures included in the current manuscript, it was not possible to also include the analysis of overall quality of life and its dimensions.

### Data sources and searches

Searches were conducted using scientific databases: PubMed (MEDLINE) and Web of Sciences (including KCI-Korean Journal Database, MEDLINE, Russian Science Citation Index, and SciELO Citation Index). The search terms used were “cancer”, “neoplasm”, HIIT, “high intensity”, “VO_{2\text{max}}”, “aerobic capacity”, “oxygen consumption”, “oxygen uptake”, “cardiorespiratory fitness”, “physical fitness”, “aerobic fitness” separated by the operators AND and OR. The following restrictions were added (a) articles published in English or Spanish, (b) published in the last 10 years and (c) not having the word “ultrasound” in the title (due to the misunderstanding...
with high-intensity focused ultrasound therapy). The search started in November 2019 and ended in February 2020.

The articles were incorporated if they fulfilled the following inclusion criteria: (a) participants had any kind of cancer, (b) the intervention included a HIT component, (c) the article reported effects on VO\textsubscript{2peak}, and (d) the design included one or more comparison groups. RCT and non-RCT were included. The following exclusion criteria were set: (a) The article was not written in English or Spanish, (b) the article was a consensus, guideline, letter to editor, conference abstract, case report, and/or a study protocol or design, and (c) the article was focused on childhood cancer. The term high intensity is defined herein to be any exercise program whose authors have described to have any “high-intensity” component including aerobic and anaerobic high-intensity components as well as resistance. Cardiovascular training is defined as any aerobic, anaerobic exercise (or a combination of both) focused on the improvement of the cardiovascular function such as cycling or exercise on a treadmill. The article selection was undertaken by the lead author (AMLP) and revised by the second researcher (DCM). There was no disagreement in the selection process.

### 2.2 Risk of bias assessment

PEDro scale was used to evaluate the risk of bias. PEDro is specific in physical therapies, commonly adopted in sport sciences\(^4^3\) and is considered a valid and reliable tool to assess eligibility, allocation to groups, blinding of allocation, and comparison between groups at baseline and its outcomes.\(^4^4\)

### 2.3 Data extraction

Following PRISMA methodology, participants, intervention, comparisons, results, and study design (PICOS) were obtained. Regarding participants, some baseline parameters were extracted, such as sample size, mean age, body mass index, physical activity level, cancer type, stage, type of treatment, and timing. Intervention characteristics included FITT principle (frequency, intensity, time, and type) together with the exercise description, intensity, progression of the exercise program, and adherence to the intervention (% attendance to the prescribed number of sessions). The activity of the comparison group(s) was also extracted. Furthermore, the outcome of the current systematic review and meta-analysis was CRFit. In this regard, VO\textsubscript{2peak} values measured during the maximal or submaximal tests could be expressed in different units: mL/min or mL/min/kg. Regardless of the units shown, articles were included in the meta-analysis whenever it was possible. Detailed information of those articles which did not report sufficient data to be included in the meta-analyses is reported in the Supplementary data (Tables S2 and S3).

Finally, the study design was also reported since RCT and non-RCT were included. Data extraction was performed by the lead author (AMLP) and then checked by another author (DCM).

### 2.4 Statistical analysis

Post-intervention means and standard deviations were extracted from the manuscript or supplemental data or calculated using reported data from high-intensity exercise group (HIEG) and the comparison group, which could be an inactive control group (CG) or a low-to-moderate intensity exercise group (LMEG).

All analyses were performed using the Review Manager Software (RevMan, 5.3).\(^4^5\) The analysis method used was the inverse variance and random effects due to the heterogeneity of articles.\(^4^6\) The standardized mean difference (SMD) was employed when there were different units of VO\textsubscript{2peak} (mL/min/kg or mL/min) whereas mean difference (MD) was used for the same VO\textsubscript{2peak} values (mL/min/kg). SMD was interpreted according to the Cochrane Handbook of Systematic Reviews.\(^4^7\) The results obtained were represented with a confidence interval (CI) of 95%. The I\textsuperscript{2} statistic model calculated heterogeneity, and Z test was used for the overall effect.

To analyze the effectiveness of the interventions on CRF, the following group comparisons were performed: (1) according to the comparison group, HIEG compared to CG and HIEG compared to LMEG; (2) according to the type of cancer, HIEG vs an inactive CG in breast cancer patients and high-intensity interventions vs an inactive CG in lung patients (types of cancer with five or more articles were included); (3) according to the timing of the intervention, high-intensity interventions compared to an inactive CG before chemotherapy, high-intensity interventions compared to an inactive CG during chemotherapy and high-intensity interventions compared to an inactive CG after chemotherapy; (4) according to the type of exercise intervention, different subgroups were compared, relating in all of them the CRF outcome of the HIEG compared to an inactive CG including: (a) interventions of 8 or less weeks of duration and programs longer than 8 weeks; (b) interventions including a resistance component and cardiovascular only; (c) interventions involving sessions with a high-intensity duration of <20 minutes and independently with a duration of 20 minutes or more.

### 3 RESULTS

#### 3.1 Study selection

A total of 214 total studies were identified in PubMed (98 studies) and Web of Science (116), and another three
articles were recovered from a previous HIIT meta-analysis. The flow diagram, in Figure 1, describes the process by which studies were included or excluded. Seventy-six studies were then excluded in the first screening and 27 in the full-text analysis. In total, 31 studies were included in the systematic review, 25 of which were incorporated in the meta-analysis.

### 3.2 Risk of bias

Table 1 shows the internal and external validity of the articles included in the systematic review measured by the PEDro scale. The mean score of all the studies was 6.27 (range 3-8) on a scale from 0 to 10, with 10 being the highest score. The items related to blinding criteria were not commonly met. This
is common in sport sciences since participants know at what intensity they have to exercise. Furthermore, therapists require exhaustive information of each participant’s need and undertake exercise training according to strict intervention protocols.

### 3.3 Participants characteristics

Participants’ baseline characteristics of the studies included in the meta-analysis are shown in Table 2 and Table S1. Information on the remaining articles can be found in the Supplementary data (Table S2). The total sample size of all included studies was 2515 participants. 1115 from the CG, 1104 in the HIEG, and 296 belonging LMEG. The mean age of the participants was 51.8 years (24-72), 51.0 in the CG, 51.6 in the HIEG, and 55.7 in the other active group. There were 22 different cancer types included in the sample.

Articles involved breast cancer (n = 10), lung cancer (n = 6), colorectal cancer (n = 4), prostate cancer (n = 2), and testicular cancer (n = 1). Eight studies reported sample

---

**Table 1** Risk of bias using PEDro scale

| Study                     | Validity | Internal item | External items | Statistic items | Total score |
|---------------------------|----------|---------------|----------------|-----------------|-------------|
| Wood et al (2020)         | Y        | Y             | Y              | N               | N           | Y           | N           | Y           | Y           | 6            |
| Lee et al (2019)          | Y        | Y             | N              | Y              | N           | N           | Y           | N           | Y           | 5            |
| Bhatia et al (2019)       | Y        | Y             | N              | Y              | N           | N           | Y           | N           | Y           | 6            |
| Alizadaeh et al (2019)    | Y        | Y             | Y              | Y              | Y           | Y           | Y           | Y           | N           | 8            |
| Northey, et al (2018)     | Y        | Y             | Y              | N              | N           | Y           | N           | Y           | 6            |
| Mijwel et al (2018)       | Y        | Y             | Y              | N              | N           | N           | Y           | Y           | 7            |
| Devin et al (2018)        | Y        | Y             | Y              | N              | N           | N           | Y           | Y           | 7            |
| Christensen et al (2018)  | Y        | Y             | N              | Y              | N           | N           | Y           | Y           | 5            |
| Karenovics et al (2017)   | Y        | Y             | N              | Y              | N           | N           | Y           | Y           | 6            |
| Wall et al (2017)         | Y        | Y             | Y              | Y              | N           | N           | Y           | N           | Y           | 7            |
| Schulz et al (2017)       | Y        | N             | N              | Y              | N           | N           | Y           | Y           | 5            |
| Persoon et al (2017)      | Y        | Y             | Y              | Y              | N           | N           | Y           | Y           | 8            |
| Banerjee et al (2017)     | Y        | Y             | Y              | N              | N           | Y           | N           | Y           | 7            |
| Adams et al (2017)        | Y        | Y             | Y              | N              | N           | N           | Y           | Y           | 8            |
| Toohey et al (2016)       | Y        | Y             | N              | N              | N           | N           | Y           | N           | 8            |
| Schmitt et al (2016)      | Y        | Y             | Y              | N              | N           | N           | Y           | N           | 6            |
| Licker et al (2016)       | Y        | Y             | N              | Y              | N           | N           | Y           | Y           | 6            |
| Dunne (2016)              | Y        | Y             | Y              | Y              | N           | Y           | Y           | N           | 8            |
| Martin et al (2015)       | Y        | Y             | Y              | Y              | N           | N           | Y           | N           | 7            |
| Moller (2015)             | Y        | Y             | Y              | Y              | N           | N           | Y           | N           | 6            |
| Kampshoff et al (2015)    | Y        | Y             | Y              | Y              | N           | N           | Y           | N           | 7            |
| Devin et al (2015)        | Y        | Y             | Y              | Y              | N           | N           | Y           | N           | 6            |
| Edvardsen et al (2015)    | Y        | Y             | Y              | Y              | N           | N           | Y           | Y           | 7            |
| West (2015)               | Y        | N             | N              | N              | N           | N           | Y           | Y           | 4            |
| Dolan (2015)              | Y        | Y             | N              | Y              | N           | N           | Y           | Y           | 5            |
| Stefanelli (2013)         | Y        | Y             | N              | Y              | N           | N           | N           | N           | 4            |
| Midgaard (2013)           | Y        | Y             | Y              | Y              | N           | N           | N           | N           | 6            |
| Andersen et al (2013)     | Y        | Y             | Y              | N              | N           | N           | N           | Y           | 6            |
| Hwang, et al (2012)       | Y        | Y             | Y              | Y              | N           | N           | N           | Y           | 6            |
| Ademsen (2009)            | Y        | Y             | Y              | Y              | N           | N           | N           | Y           | 7            |
| Study                  | Design     | Group | Sample size ( % of females) | Age mean (SD) | Cancer type (%) | Treatment (%)                                                                 | Timing | BMI mean (SD) |
|-----------------------|------------|-------|----------------------------|---------------|----------------|--------------------------------------------------------------------------------|--------|---------------|
| Lee et al (2019)      | RCT (pilot)| CG    | n = 15 (100%)              | 44.7 (11.2)   | Breast Cancer  | Chemotherapy                                                      | During  | 30.1 (7.7)    |
|                       |            | HIEG  | n = 15 (100%)              | 49.1 (7.9)    |                | Chemotherapy                                                      | During  | 33.1 (7.6)    |
| Egegaard et al (2019) | RCT        | CG    | n = 7 (71.4%)              | 65 (4.7)      | Non-small cell lung Cancer (NSCLC) | Chemoradiotherapy                                         | During  | 24.2 (1.9)    |
|                       |            | HIEG  | n = 8 (62.5%)              | 64 (5.8)      |                | Chemoradiotherapy                                         | During  | 24.1 (4.4)    |
| Northey et al (2018)  | RCT (pilot)| CG    | n = 6 (100%)               | 61.5 (7.8)    | Breast cancer  | Surgery + chemotherapy (16.67%) Surgery + radiation (33.3%) Surgery + chemotherapy + radiation (50%) | After   | NR            |
|                       |            | HIEG  | n = 6 (100%)               | 60.3 (8.1)    |                | Surgery + radiation (50%) Surgery + chemotherapy + radiation (50%) | NR     | NR            |
|                       |            | MIEG  | n = 5 (100%)               | 67.8 (7.0)    |                | Surgery (20%) Surgery + radiation (80%)                           | NR     | NR            |
| Mijwel et al (2018)   | RCT        | CG    | n = 60 (100%)              | 52.6 (10.2)   | Breast cancer  | Chemotherapy                                                      | During  | NR            |
|                       |            | HIEG-R| n = 74 (100%)              | 52.7 (10.3)   |                |                                                                 | NR     | NR            |
|                       |            | HIEG-A| n = 72 (100%)              | 54.4 (10.3)   |                |                                                                 | NR     | NR            |
| Devin et al (2018)    | RCT        | HIEG  | n = 18 (27.8%)             | 60.7 (11.7)   | Colorectal cancer | Surgery (38.9%) Surgery + chemotherapy (50%) Surgery + Chemotherapy + Radiation (11.1%) | After   | 29.8 (3.6)    |
|                       |            | HIEG-T| n = 20 (50%)               | 61.5 (10.2)   |                | Surgery (30.0%) Surgery + chemotherapy (55.0%) Surgery + radiation (10.0%) Radiation + Chemotherapy (5.0%) | After   | 24.7 (4.5)    |
|                       |            | MIEG  | n = 19 (52.6%)             | 59.8 (11.4)   |                | Surgery (36.8%) Surgery + chemotherapy (47.4%) Surgery + Chemotherapy + Radiation (15.8%) | After   | 26.5 (3.9)    |
| Karenovics et al (2017)| RCT       | CG    | n = 77 (35%)               | 24.4 (4.1)    | Lung cancer    | Surgery (100%) Chemotherapy (12%)                                 | After   | 24.4 (4.1)    |
|                       |            | HIEG  | n = 74 (45%)               | 25 (4.8)      |                | Surgery (100%) Chemotherapy (8%)                                  | After   | 25 (4.5)      |
| Wall et al (2017)     | RCT        | CG    | n = 47 (70%)               | 69.1 (8.4)    | Prostate cancer | Radiotherapy (85%)                                               | During  | NR            |
|                       |            | HIEG  | n = 50 (0%)                | 69.1 (9.4)    |                | Radiotherapy (92%)                                               | During  | NR            |

(Continues)
| Study               | Design          | Group | Sample size (% of females) | Age mean (SD) | Cancer type (%) | Treatment (%) | Timing          | BMI mean (SD) |
|--------------------|-----------------|-------|---------------------------|---------------|-----------------|---------------|----------------|---------------|
| Schulz et al (2017) | Pilot study (non-randomized) | CG    | n = 11 (100%)             | 56.9 (7.0)    | Breast cancer   | Surgery (45.45%) Chemotherapy (63.63%) Radiotherapy (100%) Hormonal therapy (90.91%) | During | NR            |
|                    |                 | HIEG  | n = 15 (100%)             | 51.9 (9.8)    |                 | Surgery (60%) Chemotherapy (80%) Radiotherapy (40%) Hormonal therapy (66.7%) | During | NR            |
| Persoon et al (2017) | RCT             | CG    | n = 55 (33%)              | 56            | Multiple myeloma (53%) (Non-)Hodgkin lymphoma (47%) | NR            | Afer           | NR            |
|                    |                 | HIEG  | n = 54 (46%)              | 53.5          | Multiple myeloma (54%) (Non-)Hodgkin lymphoma (46%) | NR            | Afer           | NR            |
| Banerjee et al (2017) | Feasability RCT | CG    | n = 30 (10%)              | 72.5 (8.40)   | Bladder cancer  | Surgery (99%) Chemotherapy (17%) | Before | 26.91 (11.60) |
|                    |                 | HIEG  | n = 30 (13%)              | 71.6 (6.8)    |                 | Surgery (100%) Chemotherapy (33%) | Before | 27.09 (13.38) |
| Adams et al (2017)  | RCT             | CG    | n = 28 (0%)               | 43.3 (9.9)    | Testicular cancer | Surgery (96.4%) Chemotherapy (28.6%) Radiation (17.9%) | After | NR            |
|                    |                 | HIEG  | n = 35 (0%)               | 40.0 (11.6)   |                 | Surgery (88.6%) Chemotherapy (42.9%) Radiation (17.1%) | After | NR            |
| Toohey et al (2016) | RCT (pilot)     | HIEG  | n = 8 (100%)              | 47.25 (13.49) | Colon (6.25%)Cervical (6.25%) Melanoma (6.25%) Ovarian (12.5%) Breast (56.25%) Breast and uterine (6.25%) Breast and liver (6.25%) | After | NR            |
|                    |                 | MIEG  | n = 8 (100%)              | 55.88 (11.81) |                 | Surgery (18.75%) Surgery + chemotherapy (12.5%) Surgery + radiation (6.25%) Surgery + Chemotherapy+Endocrine (12.5%) Surgery + Chemotherapy+Radiation + Endocrine (50%) | After | NR            |
| Schmitt et al (2016) | RCT             | HIEG  | n = 13 (100%)             | 53 (8)        | Breast (85%) Ovarian (8%) Non-invasive urotelial (8%) Metastases (15%) | Surgery (100%) Chemotherapy (54%) Radiation (69%) Antihormonal (69%) | After | 27.0 (5.3)   |
|                    |                 | LMIEG | n = 13 (100%)             | 54 (9)        | Breast (77%) colon (8%) vaginal (8%) Non-Hodgkin lymphoma (8%) Metastases (8%) | Surgery (100%) Chemotherapy (69%) Radiation (69%) Antihormonal (54%) | After | 26.2 (4.3)   |

(Continues)
| Study            | Design     | Group | Sample size (% of females) | Age mean (SD) | Cancer type (%)       | Treatment (%)                              | Timing  | BMI mean (SD) |
|------------------|------------|-------|----------------------------|---------------|-----------------------|--------------------------------------------|---------|---------------|
| Dunne et al (2016) | RCT        | CG    | n = 17 (23.5%)             | 62            | Colorectal liver metastasis | Chemotherapy (60%)                          | Before  | 29.7 (4.2)   |
|                  |            | HIEG  | n = 20 (35%)               | 61            |                        | Chemotherapy (58.82%)                       | Before  | 29.7 (4.2)   |
| Martin, et al (2015) | RCT       | CG    | n = 35 (0%)                | 66.9 (6.6)    | Prostate cancer        | Surgery (77.14%) Radiation (28.57%) Brachytherapy (11.43%) ADT (20%) | After   | 28 (3.7)     |
|                  |            | HIEG  | n = 27 (0%)                | 65.3 (7)      |                        | Surgery (81.48%) Radiation (18.52%) Brachytherapy (11.11%) ADT (11.11%) | After   | 27.6 (4.1)   |
|                  |            | LIEG  | n = 25 (0%)                | 65 (6.3)      |                        | Surgery (92%) Radiation (8%) ADT (12%)     | After   | 26.4 (2.8)   |
| Martin, et al (2015) | RCT       | CG    | n = 40(100%)               | 57.2 (9.8)    | Breast cancer          | Surgery (100%) Chemotherapy (67%) Radiation (71%) Hormone (98%)         | After   | 26.3 (5.2)   |
|                  |            | HIEG  | n = 13 (100%)              | 53.5 (9)      |                        | Surgery (100%) Chemotherapy (77%) Radiation (54%) Hormone (85%)         | After   | 27.9 (5.3)   |
|                  |            | LIEG  | n = 19(100%)               | 58.2 (9.6)    |                        | Surgery (100%) Chemotherapy (63%) Radiation (90%) Hormone (82%)         | After   | 26.6 (4.8)   |
| Møller et al (2015) | Feasibility RCT | CG    | n = 16 (12.5%)             | 46.95 (9.19)  | Colon and breast cancer | Chemotherapy                                | During  | 25.54 (4.90) |
|                  |            | HIEG  | n = 15 (7.14%)             | 57.17 (10.51) |                        | Chemotherapy                                | During  | 24.39 (5.27) |
|                  |            | LIEG  | n = 77(100%)               | 48.49 (8.41)  |                        | Chemotherapy                                | During  | 23.8 (2.59)  |
| Kampshoff et al (2015) | RCT       | CG    | n = 92 (78%)               | 54 (10.9)     | Breast (63%) Colon (17%) Ovarian (6%) Lymphoma (9%) Cervix (2%) Testicles (4%) | Surgery (88%) Radiation (53%) Surgery + radiation (51%) Immunotherapy (20%) Homonal therapy (47%) | After   | NR          |
|                  |            | HIEG  | n = 91 (80%)               | 54 (11.0)     | Breast (68%) Colon (17%) Ovarian (4%) Lymphoma (10%) Testicles (1%) | Surgery (91%) Radiation (51%) Surgery + radiation (45%) Immunotherapy (18%) Homonal therapy (50%) | After   | NR          |
|                  |            | LMIEG | n = 95 (82%)               | 53 (11.3)     | Breast (65%) Colon (20%) Ovarian (3%) Lymphoma (9%) Cervix (2%) | Surgery (92%) Radiation (43%) Surgery + radiation (41%) Immunotherapy (26%) Homonal therapy (42%) | After   | NR          |

(Continues)
| Study                  | Design         | Group | Sample size (% of females) | Age mean (SD) | Cancer type (%) | Treatment (%)                                                                 | Timing          | BMI mean (SD) |
|------------------------|----------------|-------|----------------------------|---------------|----------------|--------------------------------------------------------------------------------|----------------|---------------|
| Devin et al (2015)     | RCT            | HIEG  | n = 30 (40%)               | 61 (11.1)     | Colonrectar cancer | Surgery (30.0%) Surgery + chemotherapy (50.0%) Surgery + radiation (3.3%) Surgery + chemotherapy + radiation (13.3%) Radiation + chemotherapy (3.3%) | After           | 27.1 (4.8)   |
|                        |                | MIEG  | n = 17 (52.9)              | 61.5 (10.8)   |                | Surgery (41.2%) Surgery + chemotherapy (41.2%) Surgery + chemotherapy + radiation (17.6%) | After           | 26.4 (3.4)   |
| Edvardsen et al (2015) | RCT            | CG    | n = 31 (52%)               | 65.9 (8.5)    | Lung cancer    | Surgery (100%) Chemotherapy (29%) Radiation (13%)                              | After surgery   | 25.1 (5.2)   |
|                        |                | HIEG  | n = 30 (57%)               | 64.4 (9.3)    |                | Surgery (100%) Chemotherapy (30%) Radiation (10%)                              | After surgery   | 25.4 (5.1)   |
| West (2015)            | Pilot study    | CG    | n = 13 (31%)               | 72            | Rectal cancer  | Chemoradiation (100%)                                                         | Before surgery  | 24.9 (3.9)   |
|                        | (non-randomized)| HIEG  | n = 22 (36%)               | 64            |                | Chemoradiation (100%)                                                         | Before surgery  | 27.4 (5.1)   |
| Dolan et al. (2015)    | RCT            | CG    | n = 10                     | 59.4 (9)      | Breast cancer  | Surgery (100%) Chemotherapy (60%) Radiation (70%) Hormonetherapy (70%)         | After           | 24.8 (4.4)   |
|                        |                | HIEG  | n = 12                     | 56.2 (9)      |                | Surgery (100%) Chemotherapy (75%) Radiation (58.3%) Hormonetherapy (66.67%)    | After           | 25.8 (5.8)   |
|                        |                | MIEG  | n = 11                     | 56.3 (9)      |                | Surgery (100%) Chemotherapy (63.63%) Radiation (63.63%) Hormonetherapy (54.54%) | After           | 23.9 (3.1)   |
| Stefanelli et al (2013)| RCT            | CG    | n = 40 (42.5%)             | 64.8 (7.3)    | NSCLC          | NR                                                                            | Under lobectomy | 27.6 (3.5)   |
|                        |                | HIEG  |                           | 65.5 (7.4)    |                | NR                                                                            | Under lobectomy | 25.6 (4.5)   |

(Continues)
| Study                | Design | Group | Sample size (% of females) | Age mean (SD) | Cancer type (%)                                                                 | Treatment (%)      | Timing  | BMI mean (SD) |
|---------------------|--------|-------|----------------------------|---------------|--------------------------------------------------------------------------------|-------------------|---------|---------------|
| Andersen et al (2013) | RCT    | CG    | n = 107 (72%)              | 47.8 (10.4)   | Breast (47.66%) Bowel (14.02%) Ovaries (8.41%) Testicles (6.54%) Oesopagus (0.93%) Brain (1.87%) Cervix (1.87%) Pharynx (0.93%) Pancreas (1.87%) Stomach (0.93%) Other diagnosis (5.61%) Hematological (9.43%) | NR                | During  | NR            |
| HIEG                |        |       | n = 106 (79.2%)            | 47.1 (10.8)   | Breast (49.05%) Bowel (13.21%) Ovaries (10.38%) Testicles (6.6%) Oesopagus (0.94%) Brain (0.94%) Cervix (1.88%) Pharynx (1.88%) Pancreas (0.94%) Stomach (0.94%) Other (2.83%) Hematological (10.38%) | NR                | During  | NR            |
| Hwang et al (2012)  | RCT    | CG    | n = 11 (36.4%)             | 58.5 (8.2)    | Lung cancer                                                                     | Surgery (36.4%) Chemotherapy (45.6%) Radiotherapy (45.5%) | During  | 23.1 (2.6)    |
|                     |        | HIEG  | n = 13 (61.5%)             | 61.0 (6.3)    |                                                                                   | Surgery (69.3%) Chemotherapy (76.9%) Radiotherapy (61.5%) | During  | 22.6 (2.4)    |
|                     |        |       |                            |               | (Continues)                                                                      |                   |         |               |
| Study          | Design | Group | Sample size (% of females) | Age mean (SD) | Cancer type (%) | Treatment (%) | Timing | BMI mean (SD) |
|---------------|--------|-------|---------------------------|---------------|----------------|---------------|--------|---------------|
| Adamsen et al (2009) | RCT    | CG    | n = 134 (70.9%)           | 47.2 (10.6)   | Breast (44.03%) Bowel (12.68%) Ovaries (8.2%) Testicles (6.7%) Esophagus (2.23%) Brain (2.98%) Cervix (1.5%) Pharynx (0.74%) Pancreas (1.5%) Stomach (1.5%) Other (6.7%) Hematological malignancies (11.2%) | Chemotherapy | During | NR            |
| HIEG          |        |       | n = 135 (74.8%)           | 47.2 (10.7)   | Breast (44.44%) Bowel (13.33%) Ovaries (11.85%) Testicular (5.18%) Esophagus (1.48%) Brain (0.74%) Cervix (2.96%) Pharynx (1.48%) Pancreas (0.74%) Stomach (0.74%) Other (7.4%) Hematological malignancies (9.63%) | Chemotherapy | During | NR            |

Abbreviations: BMI, Body Mass Index; CG, control group; HIEG, high-intensity exercise group; HIEG-A, high-intensity exercise group with aerobic component; HIEG-R, high-intensity exercise group with resistance component; HIEG-T, high-intensity exercise group with tapered frequency; MIEG, moderate-intensity exercise group; NR, no reported; SD, standard deviation.
| Study               | Group | Duration | Sessions duration/ frequency | Exercise description                                                                 | Intensity progression and control                                                                 | Attendance       |
|--------------------|-------|----------|-------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------|
| Lee et al (2019)   | CG    | 8 wk     | 30 min/ 3 times per week      | Current level of Physical activity                                                   | Intervals at 90% (W Peak Power) 2 min at 10% (W Peak Power) Additional control: HR               | Sessions: 82.3%  |
|                    | HIEG  | 8 wk     |                               | Cycle exercise HIIT: 5 min warm-up, 20 min HIIT (7 × 1 min) and 5 min cooldown        |                                                                                                  | Simple size: 100%|
| Egegaard et al (2019) | CG    | 7 wk     | 20 min/ 5 times per week      | Daily life                                                                            | Activity tracker (Garmin® vívosmart®)                                                               | Sessions: 90.0%  |
|                    | HIEG  | 7 wk     |                               | Ergometer cycle exercise: 5 min warm-up 1st and 3rd Intervals: 5x 30 s with 30 s rest 2nd interval: continuous cycling | Warm-up: 50%-60% (W Peak Power) 1st, 3rd interval 80%-95% (W Peak Power) 2nd interval: 80% (W Power Peak) Additional control: HR | Simple size: 100%|
| Northey et al (2018) | CG    | 12 wk    | 20-30 min/ 3 times per week   | 5 min warm-up and cooldown 4-7x 30 s cycling intervals with 2 min active recovery     | Warm-up and cooldown 50% PP Intervals of 95 and 115 rpm 90% of their maximum by the fourth interval 1 more interval per week Additional control: HR and RPE | Sessions: 79.4 ± 12.0% |
|                    | HIEG  | 12 wk    |                               | 5 min warm-up and cooldown 20 min aerobic                                               | Warm-up and cooldown 50% PP Aerobic 55%-65% PP Additional control: HR and RPE                       | Simple size: 100%|
|                    | MIEG  | 12 wk    |                               |                                                                                      |                                                                                                  | Sessions: 78.7 ± 13.2% |

(Continues)
| Study          | Group | Duration | Sessions duration/frequency | Exercise description                                                                 | Intensity progression and control                      | Attendance |
|---------------|-------|----------|-----------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------|------------|
| Mijwel et al (2018) | CG    | 16 wk    | 60 min/2 times per week     | Written American College of Sports Medicine exercise recommendations                  | Warm-up: 10-12 RPE                                      |           |
|               |       |          |                             | 5 min aerobic warm-up                                                                | Resistance: 70%-80% (RM)                                |            |
|               |       |          |                             | Resistance: 8-12 high-load repetitions of the major muscle groups                    | Aerobic: moderate 13-15 RPE                             |            |
|               | HIEG-R| 16 wk    |                             | Cycle exercise HIIT: 3 x 3 min intervals with 1 min recovery                         | HIIT: intervals at 16-18 RPE                            |            |
|               |       |          |                             | Cycle exercise HIIT: 3 x 3 min intervals with 1 min recovery                         | Warm-up: 10-12 RPE                                      | Sessions: 68% |
|               |       |          |                             | 5 min aerobic warm-up                                                                | Resistance: 70%-80% (RM)                                | Simple size: 88% |
|               | HIEG-A| 16 wk    |                             | Resistance: 70%-80% (RM)                                                            | Aerobic: moderate 13-15 RPE                             |            |
|               |       |          |                             | Cycle exercise HIIT: 3 x 3 min intervals with 1 min recovery                         | HIIT: intervals at 16-18 RPE                            |            |
|               |       |          |                             | 5 min aerobic warm-up                                                                | Warm-up: 10-12 RPE                                      | Sessions: 63% |
| Devin et al (2018) | HIEG  | 8 wk     | 38 min/3 times per week     | Cycling exercise                                                                     | Warm-up: 50%-70% HRpeak                                 |           |
|               |       |          |                             | 10 min warm-up 4 x 4 min cycling bouts intervals with 3 min active recovery          | Intervals: 85%-95% HRpeak                               |            |
|               |       |          |                             | Cycling exercise                                                                     | Recovery: 50%-70% HRpeak                                 |            |
|               | HIEG-T| 8 wk     |                             | 38 min/1st 4 wk: 3 times per week, 2nd 4 wk: 1 time per week                        | Additional control: RPE                                 |            |
|               |       |          |                             | Cycling exercise                                                                     | Warm-up: 50%-70% HRpeak                                 | Sessions: 100% |
|               |       |          |                             | 10 min warm-up 4 x 4 min cycling bouts intervals with 3 min active recovery          | Intervals: 85%-95% HRpeak                               | Simple size: 99.3 ± 2.2% |
|               |       |          |                             | Cycling exercise                                                                     | Recovery: 50%-70% HRpeak                                 | Simple size: 99.9 ± 0.5% |
|               |       |          |                             | 50%-70% HRpeak                                                                       | Additional control: RPE                                 |            |
| Karenovics et al (2017) | CG    | Median of 25 days | 34 min/3 times per week | 5 min warm-up                                                                       | Warm-up: 50% (WRpeak)                                   |           |
|               |       |          |                             | 2 x 10 min with 15 s cycling intervals with 15 s pauses and 4 min rest between series | Intervals: all-out effort                                |            |
|               | HIEG  |          |                             | 5 min warm-up                                                                       | Cooldown: 30% (WRpeak)                                  | Session: 87 ± 18% |
|               |       |          |                             | 5 min warm-up                                                                       | Additional control: RPE                                 | Simple size: 100% |

(Continues)
| Study                  | Group | Duration | Sessions duration/ frequency | Exercise description                                                                                      | Intensity progression and control            | Attendance |
|-----------------------|-------|----------|-----------------------------|----------------------------------------------------------------------------------------------------------|---------------------------------------------|------------|
|                       |       |          |                             | Normal physical activity and dietary routine.                                                            | Warm-up: 11-12 RPE                          | Sessions: 69% |
|                       |       |          |                             | Clinic: 5 min warm-up (Aerobic and static stretching)                                                   | Resistance: 6RM-12 RM                        | Simple size: 86% |
|                       |       |          | Clinic 60 min/ 2 times per week | Resistance: major upper and lower body muscle groups                                                   | Aerobic: 70%-90% HR in VO2max               |            |
|                       |       |          | Home-based: 150 min/week     | Weeks 1-4: 2 sets, 12 repetitions. Weeks 5-8: 3 sets, 10 repetitions. Weeks 9-12: 3 sets, 8 repetitions.| Home-based: 70%-90% HR in VO2max            |            |
|                       |       |          |                             | Weeks 13-16: 4 sets, 6 repetitions. Aerobic: 20-30 min in various machines. 5 min cooldown              |                                             |            |
|                       |       |          |                             | Home-based: 150 min aerobic                                                                              |                                             |            |
| Wall et al (2017)     | CG    | 6 months |                             |                                                                                                           |                                             |            |
|                       | HIEG  | 6 months | Clinic 60 min/ 2 times per week |                                                                                                           |                                             |            |
|                       |       |          | Home-based: 150 min/week     |                                                                                                           |                                             |            |
| Schulz et al (2017)   | CG    | 6 wk     | 69 min/ 2 times per week    | Aerobic: 15 min warm-up and 3 min cooldown, 10 x 1 min cycling intervals with 1 min active recovery.     | Warm-up 50% VO2max                          | Sessions: 97.22% |
|                       | HIEG  | 6 wk     |                             | Resistance: 4 training blocks of 2 series of 8-12 repetitions 2 series, with interserial pause (3 min, motion sequence: concentric 2 s, isometric 1 s, eccentric 4 s) | Intervals: 85%-100% VO2max                 | Simple size: 100% |
| Persoon et al (2017)  | CG    | 18 wk    | 60 min/ First 12 wk: 2 times per week. Until end: 1 time per week | Resistance: 6 standardized exercise muscles. Week 1-12: 2 series of 10 repetitions. Aerobic: 2 x 8 min cycling. Week 1-8: 30 s blocks with 60 s blocks | Resistance: 65%-80% RM                       | Sessions: 86% |
|                       | HIEG  | 18 wk    |                             |                                                                                                           | Aerobic: 30 s blocks at 65% (maximal short exercise capacity)                                    | Simple size: 92.6% |
|                       |       |          |                             |                                                                                                           | 60 s blocks at 30% (maximal short exercise capacity)                                             |            |
|                       |       |          |                             |                                                                                                           | Load adjustment every 4 wk                   |            |

(Continues)
| Study            | Group | Duration | Sessions duration/frequency | Exercise description                                                                 | Intensity progression and control                                                                                      | Attendance |
|------------------|-------|----------|----------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------|
| Banerjee et al (2017) | CG    | 8 sessions 3-6 wk | 45-50 + cooldown/ 2 times per week | Cycle ergometer 5-10 min warm-up 6 × 5 min cycling intervals with 2.5 min active recovery | Warm-up: 50 W 13-15 RPE 70%-85% HRmax (220-age) cadence 50-60 rev.min-1 Recovery 50 W Additional control: HR | Simple size: 90% |
|                  | HIEG  |           |                            |                                                                                       |                                                                                                                     |             |
| Adams, et al (2017)  | CG    | 12 wk    | 35 min/ 3 times per week   | 5 min warm-up and cooldown 4 × 4 min walking/running intervals with 3 min active recovery | Warm-up: at ± 5% of the ventilatory threshold Intervals: 75% - 95% VO2max Recovery: 5%-10% of the ventilatory threshold Additional control: HR | Sessions: 99% Simple size: 100% |
|                  | HIEG  | 12 wk    |                            |                                                                                       |                                                                                                                     |             |
| Toohey et al (2016)  | HIEG  | 12 wk    | 20-30 min/ 3 times per week | 5 min warm-up 3 to 7 × 30 s cycling or treadmill intervals with 1 min rest 5 min cooldown | Intervals ≥ 85% (HRmax) Additional control: RPE and blood pressure                                                                 | Sessions: 93.75% Simple size: 100% |
|                  | MIEG  | 12 wk    | 30 min/ 3 times per week   | 5 min warm-up 20 min cycle continuous Aerobic 5 min cooldown                            |                                                                                                                     |             |
| Schmitt et al (2016) | HIEG  | 3 wk 8 sessions | 25 min/ 3 times per week   | 5 min warm-up 8 × 1 min intervals walking 2 min active recovery                         | Warm-up: 70% (HRpeak) Intervals: >95% (HRpeak) 93% participants all sessions                                                                 |             |
|                  | LMIEG | 3 wk 75 min/6 sessions |                      | 60 min walking 15 min indoor cycling                                                  |                                                                                                                     |             |
| Dunne et al (2016)  | CG    | 4 wk     | 30 min + warm-up + cooldown/12 sessions | Cycle ergometer exercise Warm-up Intervals of high and moderate intensity | High intensity > 90% (VO2 peak) Moderate intensity > 60% (VO2peak)                                                                 | Sessions: 99% Simple size: 95% |
|                  | HIEG  | 4 wk     |                            |                                                                                       |                                                                                                                     |             |
| Study                  | Group | Duration | Sessions duration/frequency | Exercise description                                                                 | Intensity progression and control                                                                 | Attendance       |
|------------------------|-------|----------|----------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------|
| West et al (2015)      | CG    | 6 wk     | 30 min First 2 sessions, 40 min rest of sessions/3 times per week | 5 min warm-up 3 min braked cycle ergometer intervals with 2 min intervals 5 min cooldown | 3 min Intervals: 80% of oxygen uptake at lactate threshold 2 min intervals: 50% of the difference in work rates between peak oxygen uptake and oxygen uptake at lactate threshold | Sessions: 96% Simple size: 100% |
|                        | HIEG  | 6 wk     |                            |                                                                                      |                                                                                                |                  |
| Martin et al (2015) c) | CG    | 8 wk     | 60 min/ 3 times per week   | 25 min Aerobic (walking/jogging) 25 min resistance 10 min static stretching           | Aerobic: 75%-80% (VO2 max) Increase + 5% VO2 middle of the program Resistance: 65%-80% RM Additional control: HR | Sessions: 90% Simple size: 96% |
|                        | HIEG  | 8 wk     |                            |                                                                                      |                                                                                                |                  |
|                        | LIEG  | 8 wk     |                            |                                                                                      |                                                                                                |                  |

(Continues)
| Study | Group | Duration | Sessions duration/ frequency | Exercise description | Intensity progression and control | Attendance |
|-------|-------|----------|-----------------------------|----------------------|----------------------------------|------------|
| Martin et al (2015) a) | CG | 8 wk | 60 min/ 3 times per week | 25 min Aerobic (walking/jogging) 25 min resistance 10 min static stretching | Aerobic: Week 1-4 75% (VO2 max)/ Week 5-8 80% (VO2 max) Increase +5% VO2 middle of the program Resistance: 65%-80% RM Additional control: HR | Sessions: 90% Simple size: 96% |
| | HIEG | 8 wk | 60 min/ 3 times per week | 25 min Aerobic (walking/jogging) 25 min resistance 10 min static stretching | | |
| LIEG | 8 wk | 60 min/ 3 times per week | 25 min Aerobic (walking/jogging) 25 min resistance 10 min static stretching | | | |
| Møller et al (2015) a) and b) | CG | 12 wk | 90 min (hiit sessions)/9 h per week | High-intensity sessions: 30 min warm-up 45 min resistance: 3 series of 5-8 repetitions 15 min cycling aerobic interval training: cooldown (stretching and coordination training) Low- intensity sessions: 30-90 min of body awareness, relaxation or massage | Resistance: 70%-100% RM- 5.5 METSs Aerobic: 70-250 W, 85%-95% (HRmax) 15 METs | a) Sessions: 74% Simple size: 82% b) Sessions: 50% Simple size 75% |
| | HIEG | 12 wk | 90 min (hiit sessions)/9 h per week | | | |
| | LIEG-H | 12 wk | 30 min per day/ 5 times per week | Low/moderate recreational physical activity level of 30 min/day and 10 000 steps/day | Pedometer data | | 

(Continues)
| Study                  | Group | Duration | Sessions duration/ frequency | Exercise description                                                                 | Intensity progression and control                                                                 | Attendance                      |
|-----------------------|-------|----------|------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------|
| Kampshoff et al (2015)| CG    | 12 wk    |                              | Resistance: six exercise large groups 2 series of 10 rep<br>Aerobic: 1st-4th week: 2 × 8 min cycling intervals 30 s + 60 s blocks<br>4th-end: 2 × 8 min cycling intervals 30 s + 30 s blocks<br>5th week-end additional Aerobic session: 8 min of cycling intervals 30 s + 30 s blocks and 8 min 3 × 5 min continuous ergometer with 1 min rest | Resistance: 70%-85% (RM)<br>Aerobic: 30 s Interval 65% maximum short exercise capacity (MSEC) 60 s Interval: 30% (MSEC) Continuous ergometer: 80% (HRR) Load adjustment every 4 wk | Sessions: 74% and more than 80% of the sessions<br>Simple size: 92% |
|                       | HIEG  | 12 wk    | Depending on de week/ 2 times per week |                                                                                      |                                                                                                  |                                  |
|                       | LMIEG | 12 wk    | Depending on de week/ 2 times per week | Resistance: six exercise large groups 2 series of 10 rep<br>Aerobic: 1st-4th week: 2 × 8 min cycling intervals 30 s + 60 s blocks<br>4th-end: 2 × 8 min cycling intervals 30 s + 30 s blocks<br>5th week-end additional Aerobic session: 8 min of cycling intervals 30 s + 30 s blocks and 8 min 3 × 5 min continuous ergometer with 1 min rest | Resistance: 40-55% (RM)<br>Aerobic: 30 s Interval 65% maximum short exercise capacity (MSEC) 60 s Interval: 30% (MSEC) Continuous ergometer: 40%-50% (HRR) Load adjustment every 4 wk | Sessions: 70%                     |
| Devin et al (2015)    | HIEG  | 4 wk     | 38 min/ 3 times per week      | 10 min warm-up<br>4 × 4 min cycling intervals with 3 min active recovery               | Warm-up: 50%-70% (HRpeak), W and cadence<br>Intervals: 85%-95% (HRpeak) Recovery: 50%-70% (HRpeak) Additional control: RPE | Sessions: 100% Simple size: 97.0% |
|                       | MIEG  | 4 wk     | 50 min/ 3 times per week      | Continuous cycling                                                                   | 50%-70% (HRpeak)<br>Additional control: RPE, W and cadence<br>50% (HRpeak) | Sessions: 100% Simple size: 97.1% |

(Continues)
### TABLE 3 (Continued)

| Study                  | Group   | Duration | Sessions duration/frequency | Exercise description                                                                 | Intensity progression and control                                      | Attendance |
|------------------------|---------|----------|-----------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------|
| Edvardsen et al (2015) | CG      | 20 wk    | 60 min/ 3 times per week    | Warm-up<br>Interval uphill treadmill walking<br>Resistance 3 series of leg press, leg extension, back extension, seat row, bicep curls, and chest-and-shoulder press | Intervals 80%-95% (HRpeak)<br>Resistance: 6-12 RM<br>Additional control: RPE | Sessions: 88 ± 29%<br>Simple size: 83% |
|                        | HIEG    | 20 wk    |                             |                                                                                        |                                                                          |            |
| Dolan at al. (2015)    | CG      | 6 wk     | 3 times per week            | Walking exercise<br>Intervals: Starting in 3.22 km and progressing to 4.02 km by week 5 | Intervals from 50%-60% VO2 to 60%-90% VO2<br>Additional control: Distance and HR | Sessions: 99%<br>Simple size: 100% |
|                        | HIEG    | 6 wk     |                             |                                                                                        |                                                                          |            |
|                        | MIEG    | 6 wk     |                             |                                                                                        |                                                                          |            |
| Stefanelli et al (2013)| CG      | 3 wk     | 180 min/ 15 sessions       | Respiratory exercise<br>Aerobic: Rowing, cycle ergometer, and treadmill<br>Aerobic 70% CPET<br>+10 W when the patient was able to tolerate the set load for 30 min |                                                                          |            |
|                        | HIEG    | 3 wk     |                             |                                                                                        |                                                                          |            |
| Hwang et al (2012)     | CG      | 8 wk     | 30-40 min/ 3 times per week | General exercise instructions and Theraband® Elastic Band<br>Treadmill o cycling ergometer sessions<br>10 min warm-up<br>2-5 min intervals with an active recovery<br>5 min cooldown | Intervals: 80% (VO2peak)<br>15-17 RPE<br>Recovery: 60% (VO2peak)<br>11-13 RPE<br>Load adjustment every 1-2 wk<br>Additional control: HR, blood pressure and oxygen saturation | Sessions: 71.2%<br>Simple size: 85% |
|                        | HIEG    | 8 wk     |                             |                                                                                        |                                                                          |            |

(Continues)
size comprised of different types of cancer patients. Eight interventions took place before surgery, eleven were during chemotherapy, and eight occurred after treatment. Patients' mean Body Mass Index ranged from 22.6 to 33.1 kg/m², and none were physically active prior to the study.

### 3.4 Interventions characteristics

The exercise protocols included in the meta-analysis are described in Table 3. The characteristics of those not included can be seen in the Supplementary data (S3). High-intensity programs were supervised in clinics, laboratories, exercise centers, outdoors, or hospitals for instance. One study was carried out in the participant's home. The interventions differed in duration: from two to five weeks, six weeks, from seven to eight weeks, twelve-week, or more than twelve weeks. There were also interventions with different lengths depending on chemotherapy duration. Also, only the results of the first six weeks of Moller et al were included in the meta-analysis because beyond that time the intervention involved only sport practice.

Regarding the FITT principle, the studies' interventions are based on the following details:

- **Frequency**: The most usual frequency was three times per week although there were programs of two times per week, four times per week, and five times per week. Mean whole session duration was 56.73 minutes with some programs of 20 minutes, from 20 to 30 minutes, 30 minutes, from 30 to 40 minutes, 40 minutes, 50 minutes, 60 minutes, and 70 minutes. As for the type of exercise, most of the studies included the interval training as the high-intensity component except three using a more continuous form of high-intensity exercise.
- **Intensity**: The cardiovascular exercise was made in cyclo-ergometers, walking or running, or using different ergometer machines with bouts of 15 seconds, 30 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes. Some of the programs started their progression in 70% or less of the maximum intensity target in the prior evaluation and 85% or more intensity. Moreover, some programs also included resistance training:
- **Time**: The mean adherence rates were 79.43% to the high-intensity interventions; aerobic only activities included resistance component; HIEG, high-intensity exercise group with aerobic component; HIEG-R, high-intensity exercise group with resistance component; HIEG-T, high-intensity exercise group with interval training; HR, heart rate; METs, Metabolic equivalent; PP, power peak; RM, repetition maximum; RPE, rate of perceived exertion; W, watts.

## Table 3 (Continued)

| Study            | Duration | Intensity progression and control | Attendance | Exercise description                                                                 | Intensity progression and control | Attendance |
|------------------|----------|----------------------------------|------------|--------------------------------------------------------------------------------------|-----------------------------------|------------|
| Adamsen et al (2009) | 6 wk     | HIEG-A                           | 90 min (full sessions)/ 9 h per week | High-intensity cycling sessions: 30 min warm-up; 3 series of 5-8 repetitions; cooldown (stretching and coordination training); Low-intensity sessions: 30-90 min of body awareness, relaxation or massage | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-T                           | 6 wk       | HIEG-T, high-intensity exercise group with interval training; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-R                           | 6 wk       | HIEG-R, high-intensity exercise group with aerobic component; PP, power peak; RM, repetition maximum; RPE, rate of perceived exertion; W, watts. | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-1                           | 6 wk       | HIEG-1, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-2                           | 6 wk       | HIEG-2, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-3                           | 6 wk       | HIEG-3, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-4                           | 6 wk       | HIEG-4, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-5                           | 6 wk       | HIEG-5, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-6                           | 6 wk       | HIEG-6, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-7                           | 6 wk       | HIEG-7, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-8                           | 6 wk       | HIEG-8, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-9                           | 6 wk       | HIEG-9, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-10                          | 6 wk       | HIEG-10, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-11                          | 6 wk       | HIEG-11, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-12                          | 6 wk       | HIEG-12, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-13                          | 6 wk       | HIEG-13, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-14                          | 6 wk       | HIEG-14, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-15                          | 6 wk       | HIEG-15, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-16                          | 6 wk       | HIEG-16, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-17                          | 6 wk       | HIEG-17, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-18                          | 6 wk       | HIEG-18, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-19                          | 6 wk       | HIEG-19, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-20                          | 6 wk       | HIEG-20, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-21                          | 6 wk       | HIEG-21, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-22                          | 6 wk       | HIEG-22, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-23                          | 6 wk       | HIEG-23, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-24                          | 6 wk       | HIEG-24, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
|                  |          | HIEG-25                          | 6 wk       | HIEG-25, high-intensity exercise group with tapered frequency; HR, heart rate; METs: | Resistance: 70%-90% RM; 3.5 METs | Attendance: 70.8% |
Interventions that focused on low and low to moderate-intensity exercise achieved an adherence rate of 88.75% regardless of exercise modality.

### 3.5 Cardiorespiratory fitness measures

The assessment of CRFit was mostly conducted using maximal or submaximal incremental test with a gas analysis to assess VO$_{2\text{peak}}$ (in mL/kg/min or mL/min). The CRFit test was carried out on a stationary bike or a treadmill. Cycle ergometer evaluations increased 5-15 W/min, 25-30 W/min, 20-30 W/min, 25 W each 3 minutes, 20-30 W/min, 10-25 W/min, or 30 W/min. Treadmill assessments increased the incline 2% every 2 minutes, or increased velocity and incline at the same time. Some interventions used field test to estimate CRFit such as the 6MWT (Six-Minute-Walking-Test) and Rockport Walk Test.

### 3.6 Cardiorespiratory fitness effects

#### 3.6.1 Overall results

Meta-analysis outcomes reported the effects of the studies reporting enough information to conduct the calculations. However, the results of those interventions that do not report enough data were reported in the Supplementary data (Table S3). The results in Figure 2 show that, in contrast to inactive CG (ie, usual care or waitlist group), the enhancement
of the VO2peak in the HIEG was higher \( (P < .00001, \text{with a SMD of} \ 0.44 \ \text{and a} \ 95\% \ CI \from 0.25 \to 0.64) \), which is considered a “moderate” effect.\(^{47}\) In comparison with an active group (low to moderate or moderate-intensity exercise), however, the results were not different \( (P = .13; \text{SMD} = 0.20 \ \text{with} \ 95\% \ CI \from −0.06 \to 0.47) \).

### 3.6.2 High-intensity exercise for cancer types

As Figure 3 reports, the effects of HIT with respect to cancer type were evaluated by separately analyzing the results in those two cancer types with 5 or more studies, breast and lung. In breast cancer, patients and survivors achieved a significant improvement \( (P < .00001; \text{MD} = 3.30 \text{mL/min/kg} \ \text{and a} \ 95\% \ CI \from 2.40 \to 4.19 \text{mL/min/kg}) \) compared with the inactive CG. Furthermore, patients with lung cancer showed a significant improvement \( (P = .04; \text{MD} = 2.09 \text{mL/min/kg} \ \text{and a} \ 95\% \ CI \from 0.13 \to 4.04 \text{mL/min/kg}) \) compared to the inactive CG.

### 3.6.3 Timing of the intervention

We also compared three different time periods (Figure 4; before, during, and after the treatments) according to the medical therapy (chemotherapy, radiotherapy, hormonotherapy, immunotherapy, and/or surgery). There was a statistically significant improvement in each of the three phases. The largest effects were observed for interventions that occurred before treatment \( (P = .01; \text{SMD} = 0.76 \ \text{with} \ 95\% \ CI \from 0.15 \to 1.38) \). The \( P \)-value for during and after treatment was .005 and .03, respectively, with a SMD slightly lower during the chemotherapy \( (\text{SMD} = 0.35, \ 95\% \ CI \from 0.11 \to 0.60) \) compared to after chemotherapy \( (\text{SMD} = 0.45 \ \text{and} \ 95\% \ CI \from 0.03 \to 0.87) \).

### 3.6.4 Exercise prescription

High-intensity protocols with or without resistance training component showed a significant improvement in VO2peak (Figure 5). Based on the SMD, the only cardiovascular training interventions had more of an effect on CRFit \( (P = .001; \text{SMD} = 0.63 \ \text{with} \ 95\% \ CI \from 0.25 \to 1.69) \) than combined cardiovascular-resistance programs \( (P < .0001; \text{SMD} = 0.32 \ \text{with} \ 95\% \ CI \from 0.17 \to 0.48) \). In this regard, the only cardiovascular training programs achieved a moderate effect according to the SMD, while those programs including resistance training showed a small effect.

Moreover, regarding the duration of the exercise programs (Figure 6), interventions of 8 weeks or less had a significantly smaller effect on VO2peak \( (P = .02; \text{SMD} = 0.32 \ \text{with} \ 95\% \ CI \from 0.06 \to 0.58) \), compared to the moderate effect reported for programs lasting longer than 8 weeks \( (P < .00001; \text{SMD} = 0.50 \ \text{with} \ 95\% \ CI \from 0.23 \to 0.78) \).
SMD = 0.62 with 95% CI from 0.36 to 0.89). Looking for the optimal number of minutes of high intensity, Figure 7 shows HIT (principal part of the session) of less than 20 minutes shows small effect size ($P = .003$; SMD = 0.32 with 95% CI from 0.11 to 0.54) in contrast to the low-moderate effect achieved by interventions with a high-intensity part of 20 or more minutes ($P = .02$; SMD = 0.40 with 95% CI from 0.06 to 0.74).

4 | DISCUSSION

This systematic review and meta-analysis aimed to evaluate the effects of HIT on the CRFit of cancer patients and survivors. In addition, the study also aimed to identify the most effective high-intensity dose to achieve the greatest improvement in CRFit outcomes. Data showed that HIT significantly improves VO$_{2\text{peak}}$ compared to an inactive control group, but there was difference in effect compared to moderate-intensity exercise. Regarding the most effective characteristics of exercise programs (Figure 8), HIT showed significant improvements in all phases of cancer treatment. The largest effect was seen in those interventions conducted before cancer treatment. A small effect was observed in interventions delivered during treatment, and a moderate effect in interventions after treatment. HIT interventions that were longer in duration than eight weeks were of at least 20 minutes, and included cardiovascular training component, were most effective in promoting improvements in CRFit. The largest VO$_{2\text{peak}}$ improvement was reported in studies that focused on cardiovascular exercise modes, including cycling or running.

The assessment of CRFit is valuable in almost all health areas given the evidence based between low levels of VO$_{2\text{peak}}$ and high risk of cardiovascular disease or mortality, in addition to the association with mortality rates attributable to cancer. Specifically, the American Heart Association showed that low CRFit level (<5 METs) in adults is linked
to high risk for mortality, while higher CRFit levels (>8 to 10 METs) considerably reduce the risks. High-intensity exercise is particularly beneficial in cancer patients with low baseline levels, as indicated by the current meta-analysis. This finding is highly relevant, as the association between physical activity and mortality is even larger among people with lower CRFit levels than those in the higher values. A previous review by Mugele et al. found that HIT did not achieve higher benefits in CRFit than moderate-intensity training; however, exercising at high intensities provides a higher glycolytic metabolism, inducing a decrease of intratumoral lactate concentration. This physiological process is highly important due to exercise lactate reverts intratumoral lactate gradient inhibiting the production after exercise and decreasing its tumoral concentration according to the Warburg effect. Consequently, inside the microenvironment, blood flow and $O_2$ increases, as well as the blood perfusion, leading to a reduction in the hypoxia. Moreover, HIT moderate the overexpression of reactive oxygen species limiting the tumor growth and inflammation.

This meta-analysis showed that breast and lung cancer patients could benefit from HIT. This finding was also observed in previous literature reviews, including all types of intensity interventions in breast and lung cancers. Our results show, however, that the timing of the HIT according to the different phases of cancer treatments may be an important variable to consider. To our knowledge, this has not been investigated by previous reviews, with these results showing that the largest effects on CRFit are produced before the initiation of cancer treatment. This enhancement in prehabilitation is crucial as it could potentially improve the response to chemotherapy and prognosis positively influence future cancer complication by infertility the tumoral microenvironment, and reduce inflammation by decreasing potential overweight or obesity. During treatment, improvements in CRFit have a smaller effect, which may be in part due to the negative effects of the treatment itself (e.g., the cardiotoxicity and heart damage) caused by cancer-treating drugs.
After therapy, the aim is to increase CRFit, where possible beyond baseline and to avoid its decline even several years after\textsuperscript{87} and to avoid the development of cardiovascular risk factors.\textsuperscript{88} However, not all cancer treatments are so likely to decline CRFit, but exercise may still play an important role due to it stimulates the upregulation of immune cells pathways (specially natural killers) associated with a reduction in tumor growth and better cancer prognosis and response to immunotherapy.\textsuperscript{89}

To our knowledge, this is the first meta-analysis to evaluate the effects of HIT on CRFit that includes resistance training. Our results showed that HIT including resistance training achieved smaller improvements in CRFit. It is important to note that resistance training based interventions as they enhance muscle function and send signs to positively modify the mentioned cancer microenvironment.\textsuperscript{84} Furthermore, other benefits of resistance training include the avoidance of sarcopenia\textsuperscript{90,91} preventing the loss of muscle mass and muscle functionality caused by chemotherapy\textsuperscript{92,93}; the reduction of myomatosis and chronic inflammation\textsuperscript{94}; the decrease in free oxidative radicals and oxidative stress\textsuperscript{95}; or the reduction of cardiovascular disease mortality\textsuperscript{96} and all-cause of deaths.\textsuperscript{97} However, the difference could be explained because of cardiovascular training interventions having higher adherence rates than interventions with resistance components. Future research may need to focus on strategies to enhance adherence in interventions with resistance components which might result in more substantial benefits.

High-intensity training interventions lasting more than eight weeks had a stronger effect in comparison with shorter programs that achieved small effects. In this regard, Toohey et al suggested that high-intensity programs must last at least four weeks in cancer survivors.\textsuperscript{40} The number of studies included in this meta-analysis that involved programs of four or fewer weeks was not enough to reach the same conclusion. Regarding HIT components, the concrete high-intensity session duration (including movement and rest) was studied, and results revealed that sessions with a high-intensity part of 20 minutes or more could lead to slightly better results than shorter ones.

The current systematic review and meta-analysis has limitations. Firstly, the included articles had to be written in English or Spanish and indexed in PubMed or Web of Sciences (which includes all journals indexed in the Journal of Citation Reports), so eligible studies may have been omitted. Secondly, the information reported in some of the
FIGURE 7  Effects of the high-intensity part of session duration in cardiorespiratory fitness

FIGURE 8  Summary of high-intensity exercise effects in cancer patients’ cardiorespiratory fitness
articles was not enough to be included in the meta-analysis or the subgroup analyses. Thirdly, the number of studies did not allow to compute a meta-analysis in other cancer types and to make subgroups for each cancer type. Finally, it must be noted that the HIT optimal program characteristics were obtained including both cancer patients and survivors mixed in the meta-analyses, which could influence the results.

4.1 | Perspective

Given that CRFit is associated with cancer patients’ survivorship, health, and quality of life, the identification of the most beneficial physical exercise intervention is of great interest. This meta-analysis, in contrast to the previous reviews, went further by offering details about the specific characteristics of exercise programs to achieve the larger CRFit improvements. The present recommendations (ie, training before cancer treatment with programs of more than 8 weeks and with a HIT part of at least 20 minutes), based on the existing scientific evidence, can also help healthcare and physical exercise professionals to prescribe adequate high-intensity exercises for cancer patients. Future studies may focus on the evaluation of the exercise dose-response depending on the type of cancer and the treatment received, as well as to better explore the differences between HIT and moderate-intensity exercise.

5 | CONCLUSIONS

High-intensity training leads to positive effects on CRFit in cancer patients and survivors. The Research showed that high-intensity exercise had greater effects in patients initiating exercise before treatment. Although high-intensity exercise had positive but smaller effects during and after treatment, HIT exercise programs should last more than 8 weeks and include at least 20 minutes of high-intensity activity. Although the results showed that the CRFit effects of adding resistance training to HIT might be limited, it is still recommended for the many other health benefits. Further research is needed to provide additional conclusions about the optimal characteristics of high-intensity exercise programs in each specific cancer type.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID
Ana Myriam Lavín-Pérez https://orcid.org/0000-0001-9357-9987

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. Gegechkori N, Haines L, Lin JJ. Long-term and latent side effects of specific cancer types. Med Clin N Am. 2017;101(6):1053-1073.
3. Jensen MT, Holtermann A, Bay H, Gyntelberg F. Cardiorespiratory fitness and death from cancer: a 42-year follow-up from the Copenhagen Male Study. Br J Sports Med. 2017;51(18):1364-1369.
4. Robsahm TE, Falk RS, Heir T, et al. Measured cardiorespiratory fitness and self-reported physical activity: associations with cancer risk and death in a long-term prospective cohort study. Cancer Med. 2016;5(8):2136-2144.
5. West MA, Asher R, Browning M, et al. Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery. Br J Surg. 2016;103(6):744-752.
6. Herrero F, Balmer J, San Juan AF, et al. Is cardiorespiratory fitness related to quality of life in survivors of breast cancer? J Strength Cond Res. 2006;20(3):535-540.
7. Myers J, McAuley P, Lavie CJ, Despres JP, Arena R, Kokkinos P. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis. 2015;57(4):306-314.
8. Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat. 2014;143(2):219-226.
9. Foulkes SJ, Howden BJ, Bigaran A, et al. Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy. Med Sci Sports Exerc. 2019;51(8):1573-1581.
10. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69:363-385.
11. Cavarretta E, Mastroiacovo G, Lupieri A, Frati G, Peruzzi M. The positive effects of exercise in chemotherapy-related cardiomyopathy. Adv Exp Med Biol. 2017;1000:103-129.
12. Nielsen KM, Offersen BV, Nielsen HM, Vaage-Nilsen M, Yusuf SW. Short and long term radiation induced cardiovascular disease in patients with cancer. Clin Cardiol. 2017;40(4):255-261.
13. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176-1191.
14. Sebio Garcia R, Yanez Brage MI, Gimenez Moolhuyzen E, Granger CL, Denely L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(3):486-497.
15. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465.
16. Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: an update meta-analysis. Medicine. 2017;96(27):e7368.
17. Jones LW, Liang Y, Pituskin EN, et al. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist. 2011;16(1):112-120.
18. Musanti R, Chao Y-Y, Collins K. Fitness and quality of life outcomes of cancer survivor participants in a community exercise program. J Adv Pract Oncol. 2019;10(1):24-37.
19. Ginzaic A, Passildas J, Gáetá E, et al. Treatment-induced cardiotoxicity in breast cancer: a review of the interest of practicing a physical activity. Oncology. 2019;96(5):223-234.
20. Scott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36(22):2297-2305.
21. Chen YJ, Li XX, Ma HK, et al. Exercise training for improving patient-reported outcomes in patients with advanced-stage cancer: a systematic review and meta-analysis. J Pain Symptom Manage. 2020;59(3):734-749. e710.
22. Scott K, Posmontier B. Exercise interventions to reduce cancer-related fatigue and improve health-related quality of life in cancer patients. Holist Nurs Pract. 2017;31(2):66-79.
23. Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Database Syst Rev. 2018;9:Cd010192.
24. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A systematic review of exercise systematic reviews in the cancer literature (2005–2017). PM R J Injury Funct Rehabil. 2017;9(s2):S347-S384.
25. Christensen JF, Simonsen C, Banck-Petersen A, et al. Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction. BJSM. open. 2019.3(1):74-84.
26. van Waart H, van Dongen JM, van Harten WH, et al. Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. Eur J Health Econ. 2018;19(6):893-904.
27. Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375-2390.
28. Tang MF, Chiu HY, Xu X, et al. Walking is more effective than yoga at reducing sleep disturbance in cancer patients: a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2019;47:1-8.
29. Nocini R, Sanchis-Gomar F, Lippi G. Physical activity and laryngeal cancer. Ann Transl Med. 2019;7(23):791.
30. Schmitt J, Lindner N, Reuss-Borst M, Holmberg HC, Sperlich B. A 3-week multimodal intervention involving high-intensity interval training in female cancer survivors: a randomized controlled trial. Physiological Rep. 2016;4(3):e12693.
31. Toohey K, Pumpa KL, Arnolda L, et al. A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. PeerJ. 2016;4:e2613.
32. Donelli da Silveira A, Beust de Lima J, da Silva Piardi D, et al. High-intensity interval training is effective and superior to moderate continuous training in patients with heart failure with preserved ejection fraction: a randomized clinical trial. Eur J Prev Cardiol. 2020;27(16):1733-1743.
33. Wiener J, McIntyre A, Janssen S, Chow JT, Batey C, Teasell R. Effectiveness of high-intensity interval training for fitness and mobility post stroke: a systematic review. PM R J Injury Funct Rehabil. 2019;11(8):868-878.
34. Edvardsen E, Skjonsberg OH, Holme I, Nordsetten L, Borchsenius F, Andersen SA. High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax. 2015;70(3):244-250.
35. Wall BA, Galvão DA, Fatehee N, et al. Exercise improves VO2max and body composition in androgen deprivation therapy-treated prostate cancer patients. Med Sci Sports Exercise. 2017;49(8):1503-1510.
36. Devin JL, Jenkins DG, Sax AT, et al. Cardiorespiratory fitness and body composition responses to different intensities and frequencies of exercise training in colorectal cancer survivors. Clin Colorectal Cancer. 2018;17(2):E269-E279.
37. Egegaard T, Rohold J, Lillelund C, Persson G, Quist M. Pre-radiation exercise in non-small cell lung cancer: a feasibility study. Rep Pract Oncol Radiother. 2019;24(4):375-382.
38. Martin EA, Battaglini CL, Hands B, Naumann F. Higher-intensity exercise results in more sustainable improvements for VO2peak for breast and prostate cancer survivors. Oncol Nurs Forum. 2015;42(3):241-249.
39. Aveseh M, Nikooie R, Aminaie M. Exercise-induced changes in tumour LDH-B and MCT1 expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice. J Physiol. 2015;593(12):2635-2648.
40. Toohey K, Pumpa K, McKane A, Cooke J, Semple S. High-intensity exercise interventions in cancer survivors: a systematic review exploring the impact on health outcomes. J Cancer Res Clin Oncol. 2018;144(1):1-12.
41. Mugele H, Freitag N, Wilhelmi J, et al. High-intensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis. J Cancer Survivor Res Pract. 2019;13(2):205-223.
42. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
43. Moseley AM, Elkins MR, Van der Wees PJ, Pinheiro MB. Using research to guide practice: the physiotherapy evidence database (PEDro). Brazil J Phys Ther. 2019;24(5):384-391.
44. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther. 2003;83(8):713-721.
45. Review Manager Software [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration; 2011.
46. Schmidt FL, Oh I-S, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(1):97-128.
47. Higgins J, Green S. 17.8. 2 Study summaries using more than one patient-reported outcome. Cochrane handbook for systematic reviews of interventions; 2011.
48. Banerjee S, Manley K, Shaw B, et al. Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial. Support Care Cancer. 2018;26(5):1515-1523.
49. Dunne DFJ, Jack S, Jones RP, et al. Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg. 2016;103(5):504-512.
lung cancer receiving targeted therapy. Support Care Cancer. 2012;20(12):3169-3177.

51. Northeij JM, Pumpa KL, Quinlan C, et al. Cognition in breast cancer survivors: a pilot study of interval and continuous exercise. J Sci Med Sport. 2019;22(5):580-585.

52. Lee K, Lopez-Torres C, Rice C, Dieli-Conwright C. Effect of high intensity interval training on cardiorespiratory fitness in breast cancer patients undergoing anthracycline chemotherapy. Med Sci Sports Exerc. 2019;51(6):242-243.

53. Alizadeh AM, Isanajed A, Sadighi S, Mardani M, Kalaghchi B, Hassan ZM. High-intensity interval training can modulate the systemic inflammation and HSP70 in the breast cancer: a randomized control trial. J Cancer Res Clin Oncol. 2019;145(10):2583-2593.

54. Persoon S, Chin AMJM, Buffart LM, et al. Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. PLoS One. 2017;12(7):e0181313.

55. Dolan LB, Campbell K, Gelmon K, Neil-Sztramko S, Holmes D, McKenzie DC. Interval versus continuous aerobic exercise training in breast cancer survivors—a pilot RCT. Support Care Cancer. 2016;24(1):119-127.

56. Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. Br Med J. 2009;Oct 13;339(1):h3410.

57. West MA, Loughney L, Lythgoe D, et al. Effect of prehabilitation on objectively measured physical fitness after neoadjuvant treatment in preoperative rectal cancer patients: a blinded interventional pilot study. Br J Anaesth. 2015;114(2):244-251.

58. Møller T, Lillevold C, Andersen C, et al. The challenge of preserving cardiorespiratory fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: a randomised feasibility study. BMJ Open Sport Exerc Med. 2015;1(1):e000021.

59. Mijwel S, Backman M, Bolam KA, et al. Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. Breast Cancer Res Treat. 2018;169(1):93-103.

60. Wood WA, Weaver M, Smith-Ryan AE, Hanson ED, Shea TC, Battaglini CL. Lessons learned from a pilot randomized clinical trial of home-based exercise prescription before allogenic hematopoietic cell transplantation. Support Care Cancer. 2020;28(11):5291-5298.

61. Bhatia C, Kayser B. Preoperative high-intensity interval training is effective and safe in deconditioned patients with lung cancer: a randomized clinical trial. J Brasileir Pneumol. 2019;51(9):712-718.

62. Devin JL, Sax AT, Hughes GL, et al. The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial. J Cancer Surviv. 2016;10(3):467-479.

63. Karenovics W, Licker M, Ellenberger C, et al. Short-term preoperative exercise therapy does not improve long-term outcome after lung cancer surgery: a randomized controlled study. Eur J Cardiothor Surg. 2017;52(1):47-54.

64. Licker M, Karenovics W, Diaper J, et al. Short-Term preoperative high-intensity interval training in patients awaiting lung cancer surgery: a randomized controlled trial. J Thorac Oncol. 2017;12(2):323-333.

65. Stefanelli F, Meoli I, Cobuccio R, et al. High-intensity training and cardiopulmonary exercise testing in patients with chronic obstructive pulmonary disease and non-small-cell lung cancer undergoing lobectomy. Eur J Cardiothor Surg. 2013;44(4):E260-E265.

66. Schulz SW, Laszlo R, Otto S, et al. Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil. 2018;40(13):1501-1508.

67. Kampshoff CS, Chinapaw MJM, Brug J, et al. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. BMC Med. 2015;13:275.

68. Alizadeh AM, Isanajed A. High-intensity interval training can modulate the systemic inflammation and HSP70 in the breast cancer: a randomized control trial. Scand J Med Sci Sports. 2019;145(10):2583-2593.

69. Midggaard J, Christensen JF, Tolver A, et al. Efficacy of multimodal exercise-based rehabilitation on physical activity, cardiorespiratory fitness, and patient-reported outcomes in cancer survivors: a randomized, controlled trial. Ann Oncol. 2013;24(9):2267-2273.

70. Adams SC, DeLorey DS, Davenport MH, et al. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: a phase 2 randomized controlled trial. Cancer. 2017;123(20):4057-4065.

71. Lee K, Kang I, Mack WJ, et al. Feasibility of high intensity interval training in patients with breast cancer undergoing anthracycline chemotherapy: a randomized pilot trial. BMC Cancer. 2019;19(1):653.

72. Kampshoff CS, van Mechelen W, Schep G, et al. Participation in and adherence to physical exercise after completion of primary cancer treatment. Inter J Behav Nutr Phys Activity. 2016;13(1):100.

73. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA. 1989;262(17):2395-2401.

74. Sawada SS, Lee IM, Naito H, et al. Cardiorespiratory fitness, body mass index, and cancer mortality: a cohort study of Japanese men. BMC Public Health. 2014;14:1012.

75. Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American heart association. Circulation. 2016;134(24):e653-e699.

76. Celis-Morales CA, Lyall DM, Anderson J, et al. The association between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness: evidence from 498 135 UK-Biobank participants. Eur Heart J. 2016;38(2):116-122.

77. van Hall G. Lactate kinetics in human tissues at rest and during exercise. Acta Physiol. 2010;199(4):499-508.

78. San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis. 2016;38(2):119-133.

79. Hofmann P. Cancer and exercise: warburg hypothesis, tumour metabolism and high-intensity anaerobic exercise. Sports. 2018;6(1):21.

80. Papadopoulos E, Santa Mina D. Can we HIIT cancer if we attack inflammation? Cancer Causes Control. 2018;29(1):7-11.

81. Lahart IM, Metssios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Systemat Rev. 2018;1:Cd011292.
82. Rosero ID, Ramirez-Velez R. Systematic review and meta-analysis of randomized, controlled trials on preoperative physical exercise interventions in patients with non-small-cell lung. *Cancer*. 2019;11(7):944.
83. Sanchis-Gomar F, Lucia A, Yvert T, et al. Physical inactivity and low fitness deserve more attention to alter cancer risk and prognosis. *Cancer Prev Res (Phila)*. 2015;8(2):105-110.
84. Koelwyn GJ, Quail DF, Zhang X, White RM, Jones LW. Exercise-dependent regulation of the tumour microenvironment. *Nat Rev Cancer*. 2017;17(10):620-632.
85. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer*. 2011;11(12):886-895.
86. Sinclair R, Navidi M, Griffin SM, Sumpter K. The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma. *Ann R Coll Surg Engl*. 2016;98(6):396-400.
87. Lakoski SG, Barlow CE, Koelwyn GJ, et al. The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study. *Breast Cancer Res Treat*. 2013;138(3):909-916.
88. Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *J Natl Cancer Inst*. 2012;104(17):1293-1305.
89. Pedersen L, Idorn M, Olofsson G, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. *Cell Metab*. 2016;23(3):554-562.
90. Villaseñor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. *J Cancer Survivor*. 2012;6(4):398-406.
91. Caan BJ, Cespedes Feliciano EM, Kroenke CH. The importance of body composition in explaining the overweight paradox in cancer-counterpoint. *Can Res*. 2018;78(8):1906-1912.
92. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res*. 2009;15(8):2920-2926.
93. Freedman RJ, Aziz N, Albanes D, et al. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. *J Clin Endocrinol Metab*. 2004;89(5):2248-2253.
94. Malietzis G, Currie AC, Athanasiou T, et al. Influence of body composition profile on outcomes following colorectal cancer surgery. *Br J Surg*. 2016;103(5):572-580.
95. Di Meo S, Napolitano G, Venditti P. Mediators of physical activity protection against ROS-linked skeletal muscle damage. *Int J Mol Sci*. 2019;20(12):3024.
96. Kamada M, Shiroma EJ, Buring JE, Miyachi M, Lee IM. Strength training and all-cause, cardiovascular disease, and cancer mortality in older women: a cohort study. *J Am Heart Assoc*. 2017;6(11).
97. Hardee JP, Porter RR, Sui X, et al. The effect of resistance exercise on all-cause mortality in cancer survivors. *Mayo Clin Proc*. 2014;89(8):1108-1115.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Lavín-Pérez AM, Collado-Mateo D, Mayo X, et al. High-intensity exercise to improve cardiorespiratory fitness in cancer patients and survivors: A systematic review and meta-analysis. *Scand J Med Sci Sport*. 2021;31:265–294. [https://doi.org/10.1111/sms.13861](https://doi.org/10.1111/sms.13861)